1. Stanley Perlman, Mark R. Denison. Coronavirus Vaccines. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA eds. Plotkin’s Vaccines. 8th edition. ISBN: 978-0-323-79058-1. Elsevier; 2023.
2. Ko HJ, Kim YJ. Antigen Delivery Systems: Past, Present, and Future. Biomol Ther (Seoul) 2023; 31: 370–387.
3. Soldatov AA, Kryuchkov NA, Gorenkov DV, et al. Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach. Vaccines
(Basel) 2025; 13: 789.
4. Suryawanshi YR. An overview of protein-based SARS-CoV-2 vaccines. Vaccine 2023; 41: 6174–6193.
5. Tscherne A, Krammer F. A review of currently licensed mucosal COVID-19 vaccines. Vaccine 2025; 61: 127356.
6. Clothier HJ, Parker C, Mallard JH, et al. Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023. Euro Surveill 2024; 29:
2400164.
7. Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory subs-
tudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med 2022; 10: 167–179.
8. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Control-
led Trial. Clin Infect Dis 2023; 76: 398–407.
9. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020; 383: 2320–2332.
10. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the
UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 398: 2258–2276.
11. Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev 2022; 12: CD015477.
12. Underwood E, Dunkle LM, Madhi SA, et al. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines 2023; 22: 501–517.
13. Lee CY, Kuo HW, Liu YL, et al. Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan. Emerg Infect Dis 2024; 30: 478–489.
14. Lin DY, Du Y, Xu Y, et al. Durability of XBB.1.5 Vaccines against Omicron Subvariants. N Engl J Med 2024; 390: 2124–2127.
15. Link-Gelles R, Chickery S, Webber A, et al. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years – VISION and IVY Networks, September 2024-Ja-
nuary 2025. MMWR Morb Mortal Wkly Rep 2025; 74: 73–82.
16. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov 2014; 13: 759–780.
17. Wei L, Dong C, Zhu W, et al. mRNA Vaccine Nanoplatforms and Innate Immunity. Viruses 2024; 16: 120.
18. Buoninfante A, Andeweg A, Genov G, et al. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines 2024; 9: 122.
19. Semenzato L, Le Vu S, Botton J, et al. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies.
JAMA 2024; 332: 1367–1377.
20. Darko DM, Seaneke SK, Karikari-Boateng E, et al. Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study. Vaccine 2024; 42:
126460.
21. Chalkias S, Pragalos A, Akinsola A, et al. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. J Infect Dis 2025; 231: e754–
e763.
22. Wagenhäuser I, Almanzar G, Förg FB, et al. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding
long-term spike-specific cellular immunity in healthcare workers. Vaccine 2024; 42: 126132.
23. Hồ NT, Hughes SG, Ta VT, et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.
Nat Commun 2024; 15: 4081.
24. Odak I, Riemann L, Sandrock I, et al. Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine. EBioMedi-
cine 2024; 99: 104947.
25. Underwood AP, Sølund C, Jacobsen K, et al. Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior
exposure to SARS-CoV-2. Front Immunol 2024; 15: 1353353.
26. Figueroa AL, Girard B, Edwards DK, et al. Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants. medRxiv 2025;
2025.05.02.25325954.
27. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med 2020; 383: 2603–2615.
28. Wong BK, Mabbott NA. Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults. Immunother Adv 2024; 4: ltae011.
29. Wilson A, Rahai N, Beck E, et al. Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States. Infect Dis Ther 2025;
14: 199–216.
30. Link-Gelles R, Rowley EAK, Irving SA, et al. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults. JAMA Netw Open 2025; 8: e2517402.
31. Murala MST, Gairola V, Sayedahmed EE, et al. Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2. Vaccines (Basel) 2025; 13: 406.
32. Mendonça SA, Lorincz R, Boucher P, et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 2021; 6: 97.
33. McCann N, O’Connor D, Lambe T, et al. Viral vector vaccines. Curr Opin Immunol 2022; 77: 102210.
34. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157–1166.
35. Wallace R, Bliss CM, Parker AL. The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 2024; 16: 973.
36. Tang J, Amin MA, Campian JL. Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review. Vaccines (Basel) 2025; 13: 524.
37. Dolzhikova IV, Tukhvatulin AI, Grousova DM, et al. Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2
Lineages Including Far-Distanced Omicron BA.5. Vaccines (Basel) 2024; 12: 1152.
38. Shoemaker K, Soboleva K, Branche A, et al. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study. Vaccines (Basel) 2024; 12:
883.
39. Ruiz-Guiñazú J, Le Gars M, Cárdenas V, et al. Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age. J Pediatric Infect Dis Soc 2024; 13: 599–601.
40. Clemens SAC, Weckx L, Milan EP, et al. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice. Vaccine 2024; 42:
3989–3998.
41. Jin Choi S, Lee W, Cheol Kim S, et al. Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine. Vaccine
2024; 42: 126118.
42. Han X, Pan H, Jin P, et al. A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China. Front Immunol 2024; 15: 1455730.
43. Le Gars M, Hendriks J, Sadoff J, et al. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine. Immunol Rev 2022; 310: 47–60.
44. Zhang Y, Bissola AL, Treverton J, et al. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disor-
ders. J Clin Med 2024; 13: 1012.
45. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in
Sweden. Lancet 2022; 399: 814–823.
46. Li X, Yang X, Ning Z. Efficacy and safety of COVID-19 inactivated vaccine: A meta-analysis. Front Med (Lausanne) 2022; 9: 1015184.
47. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, place-
bo-controlled, phase 3 trial in Turkey. Lancet 2021; 398: 213–222.
48. Luvira V, Pitisuttithum P. Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. Expert Rev Vaccines 2024; 23: 283–293.
49. Chen K, Hu J, Li J, et al. Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies. Front Immunol 2025; 16:
1618406.
50. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021; 21: 475–484.
51. Yu S, Chen S, Zhu J, et al. The roles of innate and adaptive immunity in inactivated viral vaccination-mediated protection against COVID-19. Clin Transl Med 2024; 14: e1530.
52. Li Z, Xiang T, Liang B, et al. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Front
Immunol 2021; 12: 802858.
53. Yılmaz S, Eken A, Sezer Z, et al. Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months. Front Med (Lau-
sanne) 2025; 12: 1524393.
54. Beladiya J, Kumar A, Vasava Y, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. Rev Med Virol 2024; 34:
e2507.
55. Zhang DS, Bao XP, Zhu JJ, et al. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China. Diagn Microbiol Infect Dis 2024; 109: 116253.
56. Sarwar MU, Waasia FZ, Aloqbi AA, et al. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis. J Infect Public Health 2024; 17: 245–253.